Fastest Growing Company in Massachusetts Expands Leadership Team with Key Hires in Product, International, and Operations

1 year ago

Former Drizly product veteran and other strategic hires accelerate Uwill's product innovation and expansion  BOSTON, Sept. 13, 2024 /PRNewswire/ --…

Don Norman Design Award Unveils 2024 Laureates

1 year ago

– Award Recipients to be Recognized at DNDA Summit in San Diego, November 14-15, 2024 – SAN DIEGO, Sept. 13,…

111 Inc. Announces Its Co-founders’ Strategic Share Purchase and Highlights Continued Growth and Innovation

1 year ago

SHANGHAI, Sept. 13, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company…

Mark Edwards of ViewMind Inc. Wins Business Worldwide Magazine 2024 CEO Award

1 year ago

LONDON, Sept. 13, 2024 /PRNewswire/ -- Mark Edwards, CEO of ViewMind Inc., has been named "Healthcare Technology CEO of the…

Avenues Recovery Center to Host First-Ever Recovery Block Party in Clarksville

1 year ago

In celebration of National Recovery Month, Avenues Recovery at Clarksville has announced an exciting upcoming event.CLARKSVILLE, IN / ACCESSWIRE /…

Travel With MCS for Medical Technology Ireland in September

1 year ago

BELLINGHAM, MA / ACCESSWIRE / September 13, 2024 / Later this month, Medical Components Specialists is heading to Galway, Ireland…

ATPC Partners with Photons Solar to Advance Solar PV Mounting Systems in ASEAN

1 year ago

Joint Initiative to Boost Renewable Energy Adoption and Support Carbon Neutrality in the Region KUALA LUMPUR, MALAYSIA / ACCESSWIRE /…

Acreage Enters into Amended and Restated Credit Agreement

1 year ago

Approximately $8 Million of Net Proceeds for Acreage provides funds to fuel growthNew maturity date of September 2027 enables additional…

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

1 year ago

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune…

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

1 year ago

SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB…